Vorapaxar
Vorapaxar is an antiplatelet medication that works by blocking the protease-activated receptor-1 (PAR-1) on platelets, preventing thrombin-induced platelet aggregation. It is primarily used for the reduction of thrombotic cardiovascular events in adults with a history of heart attack (myocardial infarction) or peripheral arterial disease (PAD).
Vorapaxar is an antiplatelet drug used to prevent blood clots in patients with prior heart attacks or peripheral arterial disease.
Key facts at a glance
- ATC
- B01AC26
- RxNorm
- 1537034
- Generic
- Vorapaxar
- Class
- atc-b01
- Brands
- Zontivity
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Vorapaxar is indicated to reduce thrombotic cardiovascular events (such as heart attack) in adults with a history of myocardial infarction or peripheral arterial disease. It is typically used in combination with aspirin and/or other antiplatelet agents like clopidogrel.
Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist. It selectively blocks PAR-1 on the surface of platelets, which is the primary receptor for thrombin (the most potent platelet activator). By inhibiting this receptor, it prevents thrombin-mediated platelet aggregation and reduces the formation of blood clots.
Vorapaxar carries a boxed warning for increased bleeding risk, including intracranial hemorrhage. It is contraindicated in patients with history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage. Bleeding risk should be assessed before initiation, and the drug should be discontinued at least 2-4 weeks prior to planned surgery. Common side effects include bleeding, anemia, and bruising.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy